EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Topical gene therapy for severe recessive dystrophic epidermolysis bullosa: clinical outcomes and multidisciplinary management in three patients treated with beremagene geperpavec (B-VEC) in Italy – a case series

Michela Brena, Sophie Guez, Lucia Lospalluti

Drugs in Context · 04.08.2026 · 1

DOI: 10.7573/dic.2026-2-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs in Context, online erschienen am 04.08.2026. Verfasst von Michela Brena und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Dermatology Unit, Department of Clinical Sciences and Community Health, Ca' Granda Foundation - IRCCS, Ospedale Maggiore Policlinico, Milan…. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Krystal Biotech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recessive dystrophic epidermolysis bullosa is a severe inherited blistering disorder characterized by chronic wounds, fibrosis and systemic complications. Beremagene geperpavec (B-VEC), a topical HSV1-based gene therapy delivering full-length COL7A1, has shown efficacy in clinical trials; however, real-world data remain limited. This retrospective, descriptive case series reports on three patients with genetically confirmed recessive dystrophic epidermolysis bullosa – two children and one young adult – treated between 2024 and 2026 at two Italian tertiary centres. All patients had extensive chronic skin involvement and received weekly topical B-VEC. Clinical data included wound characteristics, response to therapy, supportive care and adverse events. All patients showed clinically meaningful improvement in target wound healing. One child achieved ~70% reduction in the wound area needing treatment; the second had ~50% with shallower morphology and reduced bleeding. The adult, previously enrolled in the GEM-3 trial, achieved over 60% wound closure after reinitiating B-VEC via Italy’s 5% Italian Medicines Agency (AIFA) access programme. No treatment-related adverse events occurred. Adjunctive care included wound hygiene optimization, nutritional and iron support, and pain control. In this small descriptive case series, B-VEC was well tolerated and associated with clinically meaningful improvement in wound healing though outcomes were more variable and, in some cases, less pronounced than those reported in pivotal trials, nevertheless supporting its integration into a comprehensive care model that addresses infection risk, anaemia, nutrition, and wound management. Download the Plain Language Summary of this article: https://www.drugsincontext.com/plain-language-summaries/plain-language-summary-topical-gene-therapy-for-severe-recessive-dystrophic-epidermolysis-bullosa-clinical-outcomes-and-multidisciplinary-management-in-three-patients-treated-with-beremagene-geperpa

Schlagwörter

Stichwörter der Autor:innen

beremagene geperpavec-svdtcase-reportrecessive epidermolysis bullosa dystrophicatopical therapywound healing

Autor:innen und Institutionen

  • Pediatric Dermatology Unit, Department of Clinical Sciences and Community Health, Ca' Granda Foundation - IRCCS, Ospedale Maggiore Policlinico, Milan, Italy.
  • Foundation IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Pediatrics - Pneumoinfectivology, Milan, Italy.
  • U.O.C. Dermatology, Azienda Universitario Ospedaliera, Policlinico di Bari, Bari, Italy.

Förderung

  • Krystal Biotech

Zitieren

APA

Brena, M., Guez, S., & Lospalluti, L. (2026). Topical gene therapy for severe recessive dystrophic epidermolysis bullosa: clinical outcomes and multidisciplinary management in three patients treated with beremagene geperpavec (B-VEC) in Italy – a case series. Drugs in Context, 1. https://doi.org/10.7573/dic.2026-2-4

Vancouver

Brena M, Guez S, Lospalluti L. Topical gene therapy for severe recessive dystrophic epidermolysis bullosa: clinical outcomes and multidisciplinary management in three patients treated with beremagene geperpavec (B-VEC) in Italy – a case series. Drugs in Context. 2026:1. doi:10.7573/dic.2026-2-4

BibTeX
@article{Brena2026,
  author = {Brena, Michela and Guez, Sophie and Lospalluti, Lucia},
  title = {Topical gene therapy for severe recessive dystrophic epidermolysis bullosa: clinical outcomes and multidisciplinary management in three patients treated with beremagene geperpavec (B-VEC) in Italy – a case series},
  journal = {Drugs in Context},
  year = {2026},
  pages = {1},
  doi = {10.7573/dic.2026-2-4}
}
Kostenlos starten →